{"id":"ceftazidime-avibactam-sulbactam","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall cross-linking. Avibactam is a non-beta-lactam beta-lactamase inhibitor that protects ceftazidime from degradation by serine beta-lactamases. Sulbactam is an additional beta-lactamase inhibitor that provides broader coverage against resistant gram-negative organisms, particularly Acinetobacter baumannii.","oneSentence":"A triple-combination antibiotic that inhibits bacterial cell wall synthesis while protecting against resistance mechanisms through beta-lactamase inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:52.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated intra-abdominal infections"},{"name":"Hospital-acquired and ventilator-associated bacterial pneumonia"},{"name":"Complicated urinary tract infections"},{"name":"Multidrug-resistant gram-negative bacterial infections"}]},"trialDetails":[{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ceftazidime-avibactam + Sulbactam","genericName":"Ceftazidime-avibactam + Sulbactam","companyName":"National University of Singapore","companyId":"national-university-of-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A triple-combination antibiotic that inhibits bacterial cell wall synthesis while protecting against resistance mechanisms through beta-lactamase inhibition. Used for Complicated intra-abdominal infections, Hospital-acquired and ventilator-associated bacterial pneumonia, Complicated urinary tract infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}